Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of the coronavirus disease-2019 (COVID-19) pandemic on reproductive outcomes in patients with recurrent pregnancy loss.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC·2026
Same author

Molecular spatial profiling of chronic intervillositis of unknown etiology implies aberrant lipid metabolism.

Placenta·2026
Same author

Mid-Cycle Pain in Endometriosis: Clinical Correlations and Potential Etiological Factors.

Journal of women's health (2002)·2026
Same author

Re-evaluating endometrial injury for IVF: was a promising approach abandoned prematurely? A critical review.

Reproductive biomedicine online·2026
Same author

Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis.

Obstetrics and gynecology·2026
Same author

Endometriosis Pain Index: development of a model to predict poor pain-related quality of life after endometriosis surgery through machine learning analysis of registry data.

Pain·2026

Related Experiment Video

Updated: Jun 21, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Aromatase inhibitors: potential reproductive implications.

Mohamed A Bedaiwy1, Noha A Mousa, Robert F Casper

  • 1University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Journal of Minimally Invasive Gynecology
|July 18, 2009
PubMed
Summary

Aromatase inhibitors show potential in reproductive medicine beyond ovulation induction, particularly for endometriosis and fibroids. However, more research is needed to confirm their efficacy and safety for these conditions.

Related Experiment Videos

Last Updated: Jun 21, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Area of Science:

  • Reproductive Medicine
  • Oncology
  • Endocrinology

Background:

  • Aromatase inhibitors are primarily investigated for breast cancer prevention.
  • Their use in reproductive medicine beyond ovulation induction is under exploration.
  • Potential applications include treating symptomatic myomas and endometriosis.

Purpose of the Study:

  • To review the current evidence for aromatase inhibitor use in reproductive medicine, excluding ovulation induction.
  • To assess their potential role in managing gynecological conditions and preventing estrogen flare.

Main Methods:

  • A comprehensive literature search of MEDLINE, EMBASE, Scopus, and Web of Science databases was conducted.
  • Studies included clinical trials, cohort, observational, and in vitro research.
  • The search covered literature from inception to March 2009.

Main Results:

  • Current evidence does not support routine use of aromatase inhibitors for myomas or endometriosis without further controlled trials.
  • Aromatase inhibitors may be considered as an alternative to surgery for symptomatic myomas and endometriosis.
  • Cotreatment with aromatase inhibitors can prevent the estrogen flare associated with gonadotropin-releasing hormone agonist therapy.

Conclusions:

  • Prospective controlled trials are necessary to establish the efficacy and safety of aromatase inhibitors for endometriosis and myomas.
  • Aromatase inhibitors offer a strategy to manage estrogen flare in specific therapeutic regimens.
  • Further research is warranted to fully understand the role of aromatase inhibitors in reproductive medicine.